SGLT-2 Therapy Center

Dr. Matthew Weir discusses the pros and cons of SGLT-2 drugs with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. …

Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the impact of SGLT2 drugs on the possible improvement of kidney disease. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine …

At the the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir and Diabetes in Control Publisher Steve Freed discuss the impact of SGLT2 drugs in helpful as well as possibly harmful ways. They also look at the need for safety studies for kidney disease. Dr. Matthew Weir, MD is …

Dr. Lance Sloan talks with Diabetes in Control Publisher Steve Freed at AACE 2016. In this Exclusive Interview, Dr. Sloan discusses SGLT-associated DKA.

Results from the ongoing first large real-world evidence study of its kind published in the American Heart Association.

Study focuses on elevation of amylase and lipase levels as predictors of pancreatitis.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

Are we experiencing the next “magic bullet” in type 2 diabetes?

Study reported SGLT2 Inhibitors monotherapy might not lead to DKA events as opposed to insulin therapy.

In this week's Homerun Slides, understanding the need for cultural competence and the strategies to overcome cultural barriers.